A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea
Details
Publication Year 2002-03-15,Volume 185,Issue #6,Page 820-827
Journal Title
JOURNAL OF INFECTIOUS DISEASES
Publication Type
Journal Article
Abstract
The malaria vaccine Combination B comprises recombinant Plasmodium falciparum ring-infected erythrocyte surface antigen and 2 merozoite surface proteins (MSP1 and MSP2) formulated in oil-based adjuvant. A phase 1-2b double-blind, randomized, placebo-controlled trial in 120 children (5-9 years old) in Papua New Guinea demonstrated a 62% (95% confidence limits: 13%, 84%) reduction in parasite density in children not pretreated with sulfadoxine-pyrimethamine. Vaccinees had a lower prevalence of parasites carrying the MSP2-3D7 allelic form (corresponding to that in the vaccine) and a higher incidence of morbid episodes associated with FC27-type parasites. These results demonstrate functional activity of Combination B against P. falciparum in individuals with previous malaria exposure. The specific effects on parasites with particular msp2 genotypes suggest that the MSP2 component, at least in part, accounted for the activity. The vaccine-induced selection pressure exerted on the parasites and its consequences for morbidity strongly argue for developing vaccines comprising conserved antigens and/or multiple components covering all important allelic types.
Publisher
UNIV CHICAGO PRESS
Keywords
MEROZOITE SURFACE-ANTIGEN; EAST SEPIK PROVINCE; HIGHLY ENDEMIC AREA; STRUCTURAL DIVERSITY; CLINICAL MALARIA; WOSERA AREA; MORBIDITY; CHILDREN; EPIDEMIOLOGY; IMMUNOGENICITY
Publisher's Version
https://doi.org/10.1086/339342
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2002-03-15 12:00:00
An error has occurred. This application may no longer respond until reloaded. Reload 🗙